Elixinol Global Stock Probability Of Bankruptcy
| ELLXF Stock | USD 0 0.0009 39.13% |
Elixinol |
Elixinol Global Company chance of financial distress Analysis
Elixinol Global's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Elixinol Global Probability Of Bankruptcy | Less than 17% |
Most of Elixinol Global's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elixinol Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Elixinol Global probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Elixinol Global odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Elixinol Global financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Elixinol Global has a Probability Of Bankruptcy of 17.0%. This is 60.73% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The probability of bankruptcy for all United States stocks is 57.32% higher than that of the company.
Elixinol Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elixinol Global's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Elixinol Global could also be used in its relative valuation, which is a method of valuing Elixinol Global by comparing valuation metrics of similar companies.Elixinol Global is currently under evaluation in probability of bankruptcy category among its peers.
Elixinol Fundamentals
| Return On Equity | -0.71 | |||
| Return On Asset | -0.33 | |||
| Profit Margin | (1.72) % | |||
| Operating Margin | (1.63) % | |||
| Current Valuation | 2.06 M | |||
| Shares Outstanding | 316.27 M | |||
| Shares Owned By Insiders | 15.67 % | |||
| Shares Owned By Institutions | 4.83 % | |||
| Price To Book | 0.72 X | |||
| Price To Sales | 0.59 X | |||
| Revenue | 14.13 M | |||
| Gross Profit | 4.9 M | |||
| EBITDA | (24.15 M) | |||
| Net Income | (17.02 M) | |||
| Cash And Equivalents | 6.93 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 250 K | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 3.58 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (14.07 M) | |||
| Earnings Per Share | (0.04) X | |||
| Number Of Employees | 17 | |||
| Beta | 1.71 | |||
| Market Capitalization | 6.5 M | |||
| Total Asset | 25.33 M | |||
| Z Score | 15.0 | |||
| Net Asset | 25.33 M |
About Elixinol Global Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elixinol Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elixinol Global using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elixinol Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Elixinol Pink Sheet
Elixinol Global financial ratios help investors to determine whether Elixinol Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elixinol with respect to the benefits of owning Elixinol Global security.